Top

BMC Cancer

Published in:

Open Access 01-12-2011 | Research article

O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction

Authors: Marta Brell, Javier Ibáñez, Avelina Tortosa

Published in: BMC Cancer | Issue 1/2011

Abstract

Background

The DNA repair protein O⁶-Methylguanine-DNA methyltransferase (MGMT) confers resistance to alkylating agents. Several methods have been applied to its analysis, with methylation-specific polymerase chain reaction (MSP) the most commonly used for promoter methylation study, while immunohistochemistry (IHC) has become the most frequently used for the detection of MGMT protein expression. Agreement on the best and most reliable technique for evaluating MGMT status remains unsettled. The aim of this study was to perform a systematic review and meta-analysis of the correlation between IHC and MSP.

Methods

A computer-aided search of MEDLINE (1950-October 2009), EBSCO (1966-October 2009) and EMBASE (1974-October 2009) was performed for relevant publications. Studies meeting inclusion criteria were those comparing MGMT protein expression by IHC with MGMT promoter methylation by MSP in the same cohort of patients. Methodological quality was assessed by using the QUADAS and STARD instruments. Previously published guidelines were followed for meta-analysis performance.

Results

Of 254 studies identified as eligible for full-text review, 52 (20.5%) met the inclusion criteria. The review showed that results of MGMT protein expression by IHC are not in close agreement with those obtained with MSP. Moreover, type of tumour (primary brain tumour vs others) was an independent covariate of accuracy estimates in the meta-regression analysis beyond the cut-off value.

Conclusions

Protein expression assessed by IHC alone fails to reflect the promoter methylation status of MGMT. Thus, in attempts at clinical diagnosis the two methods seem to select different groups of patients and should not be used interchangeably.

Available only for authorised users

Bae SI, Lee HS, Kim SH, Kim WH: Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers. Br J Cancer. 2002, 86: 1888-1892. 10.1038/sj.bjc.6600372.PubMedPubMedCentral

Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG: Inactivation of the DNA repair gene O⁶-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59: 793-797.PubMed

Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC: Correlation of tumor O⁶ methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998, 16: 3310-3315.PubMed

Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol. 2002, 20: 2388-2399. 10.1200/JCO.2002.06.110.PubMed

Jones PA, Laird PW: Cancer epigenetics comes from age. Nat Genet. 1999, 21: 163-167. 10.1038/5947.PubMed

Robertson KD, Jones PA: DNA methylation: past, present and furture directions. Carcinogenesis. 2000, 21: 461-467. 10.1093/carcin/21.3.461.PubMed

Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: epigenetic joins genetics. Trends Genet. 2000, 16: 168-173. 10.1016/S0168-9525(99)01971-X.PubMed

Esteller M, García-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Eng J Med. 2000, 343: 1350-1354. 10.1056/NEJM200011093431901.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from Temozolamide in glioblastoma. N Engl J Med. 2005, 352: 997-1003. 10.1056/NEJMoa043331.PubMed

10.

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Strupp R: Clinical trial substantiates the predictive value of O6-Metylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with Temozolamide. Clin Cancer Res. 2004, 10: 1871-1874. 10.1158/1078-0432.CCR-03-0384.PubMed

11.

Crinière E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre JY, Hoang-Xuan K, Thillet J, Sanson M: MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol. 2007, 83: 173-179.PubMed

12.

Everhard S, Kaloshi G, Crinière E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J: MGMT Methylation: a marker of response to Temozolamide in low-grade gliomas. Ann Neurol. 2006, 60: 740-743. 10.1002/ana.21044.PubMed

13.

Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y: Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery. 2004, 52: 349-357. 10.1227/01.NEU.0000103422.51382.99.

14.

Watanabe T, Katayama Y, Komine C, Yoshino A, Ogino A, Ohta T, Fukushima T: O6-Methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer. 2005, 113: 581-587. 10.1002/ijc.20625.PubMed

15.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008, 9: 29-38. 10.1016/S1470-2045(07)70384-4.PubMed

16.

Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Greve J, Neyns B: MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer. 2009, 45: 146-153. 10.1016/j.ejca.2008.09.002.PubMed

17.

Shaw RJ, Hall GL, Lowe D, Liloglou T, Field JK, Sloan P, Risk JM: The role of pyrosequencing in head and neck cancer epigenetics: correlation of quantitative methylation data with gene expression. Arch Otolaryngol Head Neck Surg. 2008, 134: 251-256. 10.1001/archoto.2007.50.PubMed

18.

Preusser M, Elezi L, Hainfellner JA: Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol. 2008, 27: 388-390.PubMed

19.

Yip S, Iafrate AJ, Louis DN: Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol. 2008, 67: 1-15. 10.1097/nen.0b013e31815f65fb.PubMed

20.

Preusser M, Charles JR, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M: Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008, 18: 520-532.PubMed

21.

Andersson U, Malmer B, Bergenheim AT, Brännström T, Henriksson R: Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol. 2004, 23: 21-27.PubMed

22.

Capper D, Mittelbronn M, Meyermann R, Schittenhelm J: Pitfalls in the assessment of MGMT expression and its correlation with survival in diffuse astrocytomas: proposal of feasible immunohistochemical approach. Acta Neuropathol. 2008, 115: 249-259. 10.1007/s00401-007-0310-x.PubMed

23.

Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D: Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 2007, 25: 1470-1475. 10.1200/JCO.2006.07.4807.PubMed

24.

Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL: DNA Mismatch repair and O6-alkyguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998, 16: 3851-3857.PubMed

25.

Idbaih A, Omuro A, Ducray F, Hoang-Xuan K: Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol. 2007, 19: 606-611. 10.1097/CCO.0b013e3282f075f3.PubMed

26.

Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger SH, Wesseling P: MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest. 2007, 87: 1055-1065. 10.1038/labinvest.3700664.PubMed

27.

McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS: Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest. 1998, 78: 643-644.PubMed

28.

Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL: O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol. 2006, 24: 3431-3437. 10.1200/JCO.2006.05.7265.PubMed

29.

Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'Neil BP, James CD, Passe S, Slezak J, Giannini C: MGMT Immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol. 2008, 16: 59-65.PubMed

30.

Yachi K, Watanabe T, Ohta T, Fukushima T, Yoshino A, Ogino A, Katayama Y, Nagase H: Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Int J Oncol. 2008, 33: 469-475.PubMed

31.

Brell M, Tortosa A, Verger E, Gil JM, Viñolas N, Villà S, Acebes JJ, Caral Pons JJ, Pujol T, Ferrer I, Ribalta T, Graus F: Prognostic significance of O6 - Methilguanine DNA methyltransferase determined by promoter methylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005, 11: 5167-5171. 10.1158/1078-0432.CCR-05-0230.PubMed

32.

Ingold B, Schraml P, Heppner FL, Moch H: Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS ONE. 2009, 4: e4775-10.1371/journal.pone.0004775.PubMedPubMedCentral

33.

Preusser M: MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol. 2009, 24: 511-518.PubMed

34.

Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM: Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008, 149: 889-897.PubMedPubMedCentral

35.

Irwig L, Tosteson AN, Gatsonis C, Lau J, Colditz G, Chalmers TC, Mosteller F: Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994, 120: 667-676.PubMed

36.

Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, bezemer PD: Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002, 2: 9-10.1186/1471-2288-2-9.PubMedPubMedCentral

37.

Virgili G, Conti AA, Murro V, Gensini GF, Gusinu R: Systematic reviews of diagnostic test accuracy and the Cochrane collaboration. Intern Emerg Med. 2009, 4: 255-258. 10.1007/s11739-009-0243-6.PubMed

38.

Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003, 3: 25-10.1186/1471-2288-3-25.PubMedPubMedCentral

39.

Berman NG, Parker RA: Meta-analysis: neither quick nor easy. BMC Med Res Methodol. 2002, 2: 10-10.1186/1471-2288-2-10.PubMedPubMedCentral

40.

Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC: Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med. 2003, 138: 40-44.PubMed

41.

Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM: The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003, 56: 1129-1135. 10.1016/S0895-4356(03)00177-X.PubMed

42.

Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ. 2003, 327: 557-560. 10.1136/bmj.327.7414.557.PubMedPubMedCentral

43.

Sterne JA, Egger M: Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001, 54: 1046-1055. 10.1016/S0895-4356(01)00377-8.PubMed

44.

Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315: 629-634.PubMedPubMedCentral

45.

Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A: Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006, 6: 31-10.1186/1471-2288-6-31.PubMedPubMedCentral

46.

Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia C: Prognostic value of O(6)-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol. 2010, 97: 311-322. 10.1007/s11060-009-0031-1.PubMed

47.

Rood BR, Zhang H, Cogen PH: Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma. Neuro-Oncology. 2004, 6: 200-207. 10.1215/S1152851703000565.PubMedPubMedCentral

48.

Zhang D, Bai Y, Wang Y, Luo J, Ge Q, Qiao Y, Jia C, Lu Z: Detailed methylation patterns and protein expression profiles of MGMT in colorectal carcinoma surgical margins. Clin Biochem. 2008, 41: 19-25. 10.1016/j.clinbiochem.2007.09.010.PubMed

49.

Voelter V, Diserens AC, Moulin A, Nagel G, Yan P, Migliavacca E, Rimoldi D, Hamou MF, Kaina B, Leyvraz S, Hegi ME: Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma. Int J Cancer. 2008, 123: 1215-1218. 10.1002/ijc.23632.PubMed

50.

Martin P, Garcia-Cosio M, Santon A, Bellas C: Aberrant gene promoter methylation in plasma cell dyscrasias. Exp Mol Pathol. 2008, 84: 256-261. 10.1016/j.yexmp.2008.02.003.PubMed

51.

Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB: Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol. 2008, 26: 2299-2304. 10.1200/JCO.2007.14.5292.PubMed

52.

Lin Z, Gao M, Zhang X, Kim YS, Lee ES, Kim HK, Kim I: The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions. J Cancer Res Clin Oncol. 2005, 131: 364-370. 10.1007/s00432-004-0657-5.PubMed

53.

Furonaka O, Takeshima Y, Awaya H, Kushitani K, Kohno N, Inai K: Aberrant methylation and loss of expression of O6-Methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. Pathol Int. 2005, 55: 303-309. 10.1111/j.1440-1827.2005.01830.x.PubMed

54.

Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpré P, Rubinson L, Heitmiller RH, Yang SC, Forastiere AA, Baylin SB, Herman JG: Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003, 9: 2912-2919.PubMed

55.

Nagasaka T, Sharp GB, Notohara K, Kambara T, Sasamoto H, Isozaki H, MacPhee DG, Jass JR, Tanaka N, Matsubara N: Hypermethylation of O6-Methylguanine-DNA methyltransefarse promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin Cancer Res. 2003, 9: 5306-5312.PubMed

56.

Zhang L, Lu W, Miao X, Xing D, Tan W, Lin D: Inactivation of DNA repair gene O6-Methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis. 2003, 24: 1039-1044. 10.1093/carcin/bgg062.PubMed

57.

Matsukura S, Soejima H, Nakagawachi T, Yakushiji H, Ogawa A, Fukuhara M, Miyazaki K, Nakabeppu Y, Sekiguchi M, Mukai T: CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br J Cancer. 2003, 88: 521-529. 10.1038/sj.bjc.6600743.PubMedPubMedCentral

58.

Mellai M, Caldera V, Annovazzi L, Chio A, Lanotte M, Cassoni P, Finocchiaro G, Schiffer D: MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics. 2009, 6: 219-227.PubMed

59.

Yang SH, Kim YH, Kim JW, Park CK, Park SH, Jung HW: Methylation status of the O6-Methylguanine-deoxyribonucleic acid methyltransferase gene promoter in World Health Organization grade III gliomas. J Korean Neurosurg Soc. 2009, 46: 385-388. 10.3340/jkns.2009.46.4.385.PubMedPubMedCentral

60.

Herfarth KK, Brent TP, Danam RP, Remack JS, Kodner IJ, Wells SA, Goodfellow PJ: A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog. 1999, 24: 90-98. 10.1002/(SICI)1098-2744(199902)24:2<90::AID-MC3>3.0.CO;2-B.PubMed

61.

Yin D, Xie D, Hofmann WK, Zhang W, Asotra K, Wong R, Black KL, Koeffler HP: DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog. 2003, 36: 23-31. 10.1002/mc.10094.PubMed

62.

Lazcoz P, Munoz J, Nistal M, Pestana A, Encio IJ, Castresana JS: Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet. 2007, 174: 1-8. 10.1016/j.cancergencyto.2006.08.014.PubMed

63.

Qi J, Zhu YQ, Huang MF, Yang D: Hypermethylation of CpG island in O6-methylguanine-DNA methyltransferase gene was associated with K-ras G to A mutation in colorectal tumor. World J Gastroenterol. 2005, 11: 2022-2025.PubMedPubMedCentral

64.

Rimel BJ, Huettner P, Powell MA, Mutch DG, Goodfellow PJ: Absence of MGMT promoter methylation in endometrial cancer. Gynecol Oncol. 2009, 112: 224-228. 10.1016/j.ygyno.2008.08.038.PubMed

65.

McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ: Low O(6)-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf). 2009, 71: 226-233. 10.1111/j.1365-2265.2008.03487.x.

66.

Nagasaka T, Goel A, Notohara K, Takahata T, Sasamoto H, Uchida T, Nishida N, Tanaka N, Boland CR, Matsubara N: Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer. 2008, 122: 2429-2436. 10.1002/ijc.23398.PubMedPubMedCentral

67.

Baumann S, Keller G, Puhringer F, Napieralski R, Feith M, Langer R, Hofler H, Stein HJ, Sarbia M: The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int J Cancer. 2006, 119: 264-268. 10.1002/ijc.21848.PubMed

68.

Maxwell JA, Johnson SP, Quinn A, McLendon RE, Ali-Osman F, Friedman AH, Herndon JE, Bierau K, Bigley J, Bigner DD, Friedman HS: Quantitative analysis of O6-alkylguanine-DNA alkyltransefarse in malignant glioma. Mol Cancer Ther. 2006, 5: 2531-2539. 10.1158/1535-7163.MCT-06-0106.PubMed

69.

Chu LC, Eberhart CG, Grossman SA, Herman JG: Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer. 2006, 119: 2487-2491. 10.1002/ijc.22124.PubMed

70.

Uccella S, Cerutti R, Placidi C, Marchet S, Carnevali I, Bernasconi B, Proserpio I, Pinotti G, Tibiletti MG, Furlan D, Capella C: MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. J Clin Pathol. 2009, 62: 715-723. 10.1136/jcp.2009.064741.PubMed

71.

Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer. 2005, 113: 379-385.PubMed

72.

Munot K, Bell SM, Lane S, Horgan K, Hanby AM, Speirs V: Pattern of expression of genes linked to epigenetic silencing in human breast cancer. Hum Pathol. 2006, 37: 989-999. 10.1016/j.humpath.2006.04.013.PubMed

73.

Wolf P, Hu YC, Doffek K, Sidransky D, Ahrendt SA: O(6)- Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res. 2001, 61: 8113-8117.PubMed

74.

Lee GW, Kang JH, Kim IS, Kim HG, Ko GH, Lee JH, Kim DC, Song DH, Yang JW, Lee JS: Is inactivation of O(6)-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?. Leuk Lymphoma. 2009, 50: 1992-1998. 10.3109/10428190903312462.PubMed

75.

Herath NI, Walsh MD, Kew M, Smith JL, Jass JR, Young J, Leggett BA, Macdonald GA: Silencing of O6-methylguanine DNA methyltransferase in the absence of promoter hypermethylation in hepatocellular carcinomas from Australia and South Africa. Oncol Rep. 2007, 17: 817-822.PubMed

76.

Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D, Siegal T: Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res. 2007, 13: 1429-1437. 10.1158/1078-0432.CCR-06-2050.PubMed

77.

Martin P, Santon A, Garcia-Cosio M, Bellas C: hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies. Mod Pathol. 2006, 19: 914-921. 10.1038/modpathol.3800590.PubMed

78.

Ogawa T, Yoshida T, Tsuruta T, Saigenji K, Okayasu I: Genetic instability on chromosome 17 in the epithelium of non-polypoid colorectal carcinomas compared to polypoid lesions. Cancer Sci. 2006, 97: 1335-1342. 10.1111/j.1349-7006.2006.00334.x.PubMed

79.

Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Saglio G, Vitolo U, Pileri SA, Esteller M, Carbone A, Gaidano G: Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologia. 2004, 89: 154-164.

80.

Kim SH, Bae SI, Lee HS, Kim WH: Alteration of O6-methylguanie-DNA methyltransferase in colorectal neoplasms in sporadic and familial adenomatous polyposi patients. Mol Carcinog. 2003, 37: 32-38. 10.1002/mc.10116.PubMed

81.

Choy KW, Pang CP, To KF, Yu C, Ng JSK, Lam DSC: Impaired expression and promotor hypermethylation of O6-Methylguanine-DNA Methyltransferase in retinoblastoma tissues. Invest Ophthalmol Vis Sci (PA). 2002, 43: 1344-1349.

82.

Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR: Methylation of O6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res. 2001, 61: 827-830.PubMed

83.

Wu PF, Kuo KT, Kuo LT, Lin YT, Lee WC, Lu YS, Yang CH, Wu RM, Tu YK, Tasi JC, Tseng HM, Tseng SH, Cheng AL, Lin CH: O(6)- Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer. 2010, 68: 484-490. 10.1016/j.lungcan.2009.08.010.PubMed

84.

Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D: Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer. 2009, 115: 4783-4794. 10.1002/cncr.24546.PubMed

85.

Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, Tominaga T: Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien). 2009, 151: 1349-1358. 10.1007/s00701-009-0387-1.

86.

Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, Schramm J, Felsberg J, Kahl P, Buttner R, Pietsch T, Waha A: Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn. 2007, 9: 368-381. 10.2353/jmoldx.2007.060167.PubMedPubMedCentral

87.

Parkinson JF, Wheeler HR, Clarkson A, Mckenkie CA, Biggs MT, Little NS, Cook RC, Messina M, Robinson BG, McDonald KL: Variation of O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation in serial samples of glioblastoma. J Neurooncol. 2008, 87: 71-78. 10.1007/s11060-007-9486-0.PubMed

88.

Nakasu S, Fukami T, Baba K, Matsuda M: Immunohistochemical study for O6-Methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol. 2004, 70: 333-340. 10.1007/s11060-004-9170-6.PubMed

89.

Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, Reifenberg G, Tonn JC, Kretzschmar HA: Intratumoral homogeinity of MGMT promoter hypermetilation as demonstrated in serial stereotactic specimens for anaplastic astrocytomas and glioblastomas. Int J Cancer. 2007, 121: 2458-2464. 10.1002/ijc.23020.PubMed

90.

Everhard S, Tost J, El AH, Criniere E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Thillet J: Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol. 2009, 11: 348-356. 10.1215/15228517-2009-001.PubMedPubMedCentral

91.

Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY, Dent OF, Dhillon VS, Trent RJ, Chapuis PH, Bokey EL: Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol. 2005, 23: 2318-2324. 10.1200/JCO.2005.00.109.PubMed

92.

Stupp R: Methylguanine methyltransefrase testing in glioblastoma: when and how?. J Clin Oncol. 2007, 25: 1459-1460. 10.1200/JCO.2006.09.7139.PubMed

93.

Shen L, Kondo Y, Rosner GL, Xiao L, Supunpong Hernandez N, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa J-PJ: MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005, 97: 1330-1338. 10.1093/jnci/dji275.PubMed

94.

Candiloro IL, Dobrovic A: Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila). 2009, 2: 862-867. 10.1158/1940-6207.CAPR-09-0056.

95.

Park TJ, Han SU, Cho YK, Paik WK, Kim YB, Lim IK: Methylation of O6-Methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 2001, 92: 2760-2768. 10.1002/1097-0142(20011201)92:11<2760::AID-CNCR10123>3.0.CO;2-8.PubMed

96.

Smith-Sorensen B, Lind GE, Skotheim RI, Fossa SD, Fodstad O, Stenwig A-E, Jakobsen KS, Lothe RA: Frequent promoter hypermethylation of the O6-Methylguanine-DNA methyltransferase (MGMT) gene in testicular cancer. Oncogene. 2002, 21: 8878-8884. 10.1038/sj.onc.1205978.PubMed

97.

Bhakat KK, Mitra S: CpG methylation-dependent repression of the human O6-Methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis. 2003, 24: 1337-1345. 10.1093/carcin/bgg086.PubMed

98.

Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61: 3225-3229.PubMed

99.

Lorente A, Mueller W, Urdangarin E, Lazcoz P, Lass U, von Deimling A, Castresana JS: RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol. 2009, 19: 279-292. 10.1111/j.1750-3639.2008.00185.x.PubMed

100.

Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H: PTEN methylation and expression in glioblastomas. Acta Neuropathol. 2003, 106: 479-485. 10.1007/s00401-003-0748-4.PubMed

101.

Iafrate AJ, Louis DN: "MGMT for pt mgmt": is Methylguanine-DNA Methyltransferase testing ready for patient management?. J Mol Diagn. 2008, 10: 308-310. 10.2353/jmoldx.2008.080043.PubMedPubMedCentral

102.

Fritz G, Tano K, Mitra S, Kaina B: Inducibility of the DNA repair gene encoding O6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments. Mol Cell Biol. 1991, 11: 4660-4668.PubMedPubMedCentral

103.

Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN: Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007, 13: 2038-2045. 10.1158/1078-0432.CCR-06-2149.PubMedPubMedCentral

104.

Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, Sommer C, Kaina B: MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer. 2010, 127: 2106-2118. 10.1002/ijc.25229.PubMed

105.

Eoli M, Menghi F, Bruzzone MG, De ST, Valletta L, Pollo B, Bissola L, Silvani A, Bianchessi D, D'Incerti L, Filippini G, Broggi G, Boiardi A, Finocchiaro G: Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. 2007, 13: 2606-2613. 10.1158/1078-0432.CCR-06-2184.PubMed

106.

Jung TY, Jung S, Moon KS, Kim IY, Kang SS, Kim YH, Park CS, Lee KH: Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol Rep. 2010, 23: 1269-1276. 10.3892/or_00000760.PubMed

107.

Nagane M, Kobayashi K, Ohnishi A, Shimizu S, Shiokawa Y: Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol. 2007, 37: 897-906. 10.1093/jjco/hym132.PubMed

108.

Wiewrodt D, Nagel G, Dreimuller N, Hundsberger T, Perneczky A, Kaina B: MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer. 2008, 122: 1391-1399. 10.1002/ijc.23219.PubMed

109.

Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M: O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol. 2010, 12: 283-288.PubMedPubMedCentral

110.

Parkinson JF, Wheeler HT, McDonald KL: Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma. J Clin Neurosci. 2008, 15: 1-8. 10.1016/j.jocn.2007.06.005.PubMed

111.

Candiloro IL, Mikeska T, Hokland P, Dobrovic A: Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics Chromatin. 2008, 1: 7-10.1186/1756-8935-1-7.PubMedPubMedCentral

112.

Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME: MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol. 2010, 6: 39-51. 10.1038/nrneurol.2009.197.PubMed

113.

Anda T, Shabani HK, Tsunoda K, Tokunaga Y, Kaminogo M, Shitaba S, Hayashi T, Iseki M: Relationsip between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase π in glioblastoma and the survival of the patients treated with nimustine hydrochloride: An immunohistochemical analysis. Neurol Res. 2003, 25: 241-248. 10.1179/016164103101201445.PubMed

114.

Nakasu S, Fukami T, Jito J, Matsuda M: Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol. 2007, 68: 603-608. 10.1016/j.surneu.2006.12.053.PubMed

115.

Nakagawa T, Ido K, Sakuma T, Takeuchi H, Sato K, Kubota T: Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology. 2009, 29: 388-10.1111/j.1440-1789.2008.00983.x.

116.

Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ: The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery. 2009, 65: 866-875. 10.1227/01.NEU.0000357325.90347.A1.PubMed

117.

Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T: O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol. 2010, 15: 352-358. 10.1007/s10147-010-0065-6.PubMed

118.

Kuo LT, Kuo KT, Lee MJ, Wei CC, Scaravilli F, Tsai JC, Tseng HM, Kuo MF, Tu YK: Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer. 2009, 124: 2872-2879. 10.1002/ijc.24303.PubMed

119.

Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC: Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009, 15: 6683-6693. 10.1158/1078-0432.CCR-08-2801.PubMed

120.

Gerson SL: MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004, 4: 296-307. 10.1038/nrc1319.PubMed

121.

Esteller M, Herman JG: Generating mutations but providing chemosensitivity: the role of O6-Methylguanine DNA methyltransferase in human cancer. Oncogene. 2004, 23: 1-8. 10.1038/sj.onc.1207316.PubMed

122.

Herman JG, Baylin SB: Gene silencing in cancer is association with promoter hypermethylation. N Engl J Med. 2003, 349: 2042-2054. 10.1056/NEJMra023075.PubMed

123.

Deeks JJ: Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001, 323: 157-162. 10.1136/bmj.323.7305.157.PubMedPubMedCentral

124.

Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Bossuyt PM, Vandenbroucke-Grauls CM: Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2008, CD007394-

125.

Sasai K, Nodagashira M, Aoyanagi E, Wang L, Katoh M, Murata J, Ozaki Y, Ito T, Fujimoto S, Kaneko S, Nagashima K, Tanaka S: Careful exclusion of non-neoplastic brain components is required for an appropiate evaluation of O6-methylguanine-DAN methyltransferase status in glioma. Am J Surg Pathol. 2008, 32: 1220-1227. 10.1097/PAS.0b013e318164c3f0.PubMed

126.

Buccoliero AM, Castiglione F, Rossi Deglínnocenti D, Paglierani M, Maio V, Gheri CF, Garbini F, Moncini D, Taddei A, Sardi I, Sanzo M, Giordano F, Mussa F, Genitori L, Taddei GL: O6-Methylguanine-DNA-Methylytansefrase in recurring anaplastic ependymomas: PCR and immunohistochemistry. J Chemother. 2008, 20: 263-268.PubMed

127.

Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ: A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest. 2007, 87: 392-397.PubMed

128.

Kim JI, Suh JT, Choi KU, Kang HJ, Shin DH, Lee IS, Moon TY, Kim WT: Inactivation of O(6)-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations. Hum Pathol. 2009, 40: 934-941. 10.1016/j.humpath.2009.01.005.PubMed

129.

Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ: Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum Pathol. 2009, 40: 1534-1542. 10.1016/j.humpath.2009.01.029.PubMed

130.

Kuester D, El-Rifai W, Peng D, Ruemmele P, Kroeckel I, Peters B, Moskaluk CA, Stolte M, Monkemuller K, Meyer F, Schulz HU, Hartmann A, Roessner A, Schneider-Stock R: Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. Cancer Lett. 2009, 275: 117-126. 10.1016/j.canlet.2008.10.009.PubMed

131.

Mikami T, Yoshida T, Numata Y, Shiraishi H, Araki K, Guiot MC, Jass JR, Okayasu I: Low frequency of promoter methylation of O6-methylguanine DNA methyltransferase and hMLH1 in ulcerative colitis-associated tumors: comparison with sporadic colonic tumors. Am J Clin Pathol. 2007, 127: 366-373. 10.1309/RFETXN6387KLQ1LD.PubMed

132.

Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, Tamiya S, Tateishi N, Iwamoto Y, Tsuneyoshi M: DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol. 2006, 19: 106-114. 10.1038/modpathol.3800502.PubMed

133.

Fox EJ, Leahy DT, Geraghty R, Mulcahy HE, Fennelly D, Hyland JM, O'Donoghue DP, Sheahan K: Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer. J Mol Diagn. 2006, 8: 68-75. 10.2353/jmoldx.2006.050084.PubMedPubMedCentral

134.

135.

Koga Y, Kitajima Y, Miyoshi A, Sato K, Kitahara K, Soejima H, Miyazaki L: Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers. Ann Surg Oncol. 2005, 12: 354-363. 10.1245/ASO.2005.07.020.PubMed

136.

Kang GH, Lee S, Lee HJ, Hwang KS: Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol. 2004, 202: 233-240. 10.1002/path.1503.PubMed

137.

Zhang YJ, Chen Y, Ahsan H, Lunn RM, Lee PH, Chen CJ, Santella RM: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer. 2003, 103: 440-444. 10.1002/ijc.10852.PubMed

138.

Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG: Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002, 94: 26-32.PubMed

139.

Hayashi H, Yazawa T, Okudela K, Nagai J, Ito T, Kanisawa M, Kitamura H: Inactivation of O6-Methylguanine-DNA Methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. Jpn J Cancer Res. 2002, 93: 184-189.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/35/prepub

Title: O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction
Authors: Marta Brell
Javier Ibáñez
Avelina Tortosa
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-11-35

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases

Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation

P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation

Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma

T lymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor

Keynote webinar | Spotlight on antibody–drug conjugates in cancer